A multidisciplinary research team has developed a novel cancer therapy combining antibody fragments and molecularly engineered nanoparticles that permanently eradicates gastric cancer in mice with gastric cancer that received three doses of a treatment proven to be effective in eradicating the tumor. The researchers found . In a study that is considered revolutionary in the world of medicine and the culmination of more than five years of collaboration between Cornell University, Memorial Sloan-Kettering Cancer Center and biopharmaceutical company AstraZeneca, the nanoparticle hybrid is particularly effective at detecting tumors, indicating that they have begun searching for a new molecularly engineered therapeutic version of this immune complex, and they were able to produce antibody fragments that targeted HER2 proteins associated with stomach cancer, because these nanoparticles allowed them to carry five times more drugs than most antibodies.
And they explained that the final product was a version armed with cancer-targeting antibody fragments and more drugs, noting that not only was the disease eradicated in every mouse, but that there was no sign of tumor recurrence after nearly 200 days. and that the very hard work of this team has paid off.
